Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization
Thyroid® · 2023
DOI: 10.1089/thy.2023.0255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thyroid®, 2023. Verfasst von Paul Stewardson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Arnie Charbonneau Cancer Institute, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Molecular testing for cytologically indeterminate thyroid nodules (ITNs) is often reported with incomplete data on clinical assessment and ultrasound malignancy risk (USMR) stratification. This study aimed to clinically validate the diagnostic accuracy of a novel molecular test, assess the incremental preoperative malignancy risk of other clinical factors, and measure the impacts of introducing molecular testing at the population level.
Methods
Comprehensive clinical data were collected prospectively for the first 615 consecutive patients with ITNs in a centralized health care system following implementation of a reflexive molecular test. Clinical data include patient history, method of nodule discovery, clinical assessment, USMR, cytology, molecular testing, and surgery or follow-up along with surgeon notes on surgical decision-making. Accuracy of molecular testing and the impact of the introduction of molecular testing were calculated. A multivariable regression model was developed to identify which clinical factors have the most diagnostic significance for ITNs.
Results
A locally developed, low-cost molecular test achieved a negative predictive value (NPV) of 76–91% [confidence interval, CI 66–95%] and a positive predictive value (PPV) of 46–65% [CI 37–75%] in ITNs using only residual material from standard liquid cytology fine-needle aspiration (FNA). Sensitivity was highest (80%; [CI 63–92%]) in the American Thyroid Association (ATA) intermediate-suspicion ultrasound category, and lowest (46%; [CI 19–75%]) in the ATA high-suspicion ultrasound category. Following implementation of molecular testing, diagnostic yield increased by 14% ( p = 0.2442) and repeat FNAs decreased by 24% ( p = 0.05). Mutation was the primary reason for surgery in 76% of resected, mutation-positive patients. High-risk mutations were associated with a 58% ( p = 0.0001) shorter wait for surgery. Twenty-six percent of patients with a negative molecular test result underwent surgery. Multivariable regression highlighted molecular testing and USMR as significantly associated with malignancy.
Conclusions
Molecular testing improves preoperative risk stratification but requires further stratification for intermediate-risk mutations. Incorporation of clinical factors (especially USMR) with molecular testing may increase the sensitivity for detection of malignancy. Introduction of molecular testing offers some clinical benefits even in a low resection rate setting, and directly influences surgical decision-making. This study illustrates the importance of the local diagnostic pathway in ensuring appropriate integrated use of molecular testing for best outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Arnie Charbonneau Cancer Institute, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
- Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
- Alberta Precision Laboratories, Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
ORCID-Profile: Paul Stewardson, Markus Eszlinger, Ralf Paschke
Zitieren
APA
Stewardson, P., Eszlinger, M., Wu, J., Khalil, M., Box, A., Perizzolo, M., Punjwani, Z., Ziehr, B., Sanyal, R., Demetrick, D. J., & Paschke, R. (2023). Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization. Thyroid®. https://doi.org/10.1089/thy.2023.0255
Vancouver
Stewardson P, Eszlinger M, Wu J, Khalil M, Box A, Perizzolo M, et al. Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization. Thyroid®. 2023. doi:10.1089/thy.2023.0255
BibTeX
@article{Stewardson2023,
author = {Stewardson, Paul and Eszlinger, Markus and Wu, Jiahui and Khalil, Moosa and Box, Adrian and Perizzolo, Marco and Punjwani, Zoya and Ziehr, Bjoern and Sanyal, Ratna and Demetrick, Douglas J and Paschke, Ralf},
title = {Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization},
journal = {Thyroid®},
year = {2023},
doi = {10.1089/thy.2023.0255}
}
EUVIMED